kabutan

STELLA PHARMA CORPORATION(4888) Summary

4888
TSE Growth
STELLA PHARMA CORPORATION
446
JPY
-23
(-4.90%)
Mar 13, 3:30 pm JST
2.79
USD
Mar 13, 2:30 am EDT
Result
PTS
outside of trading hours
446
Mar 13, 11:37 pm JST
Summary Chart Historical News Financial Result
PER
PBR
5.63
Yield
ー%
Margin Trading Ratio
Stock Price
Mar 13, 2026
Opening Mar 13, 9:00 am
461 JPY 2.89 USD
Previous Close Mar 12
469 JPY 2.95 USD
High Mar 13, 10:26 am
469 JPY 2.94 USD
Low Mar 13, 9:01 am
445 JPY 2.79 USD
Volume
983,100
Trading Value
0.45B JPY 2.80M USD
VWAP
454.05 JPY 2.85 USD
Minimum Trading Value
44,600 JPY 279 USD
Market Cap
0.02T JPY 0.10B USD
Number of Trades
1,104
Liquidity & Number of Trades
As of Mar 13, 2026
Liquidity
Slightly High
1-Year Average
758
1-Year High Jan 29, 2026
11,104
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 700 2,284,100 3263.00
Feb 27, 2026 0 2,378,500
Feb 20, 2026 0 2,632,900
Feb 13, 2026 0 2,599,000
Feb 6, 2026 0 2,623,800
Company Profile
STELLA PHARMA CORPORATION is a subsidiary of Stella Chemifa. The company develops, manufactures, and sells boron-based pharmaceuticals for cancer radiotherapy.
Sector
Pharmaceuticals
STELLA PHARMA CORPORATION is a biotech venture company within the Stella Chemifa group. It specializes in the development, manufacturing, and sales of "Steboronine," a boron-based pharmaceutical for cancer radiotherapy. The company has obtained the world's first approval for a drug used in Boron Neutron Capture Therapy (BNCT). Steboronine has been launched in Japan for the treatment of unresectable locally advanced or locally recurrent head and neck cancer. Clinical trials are currently underway to expand its applications to recurrent malignant glioma and recurrent high-grade meningioma. Leveraging its strength in high-purity boron-10 enrichment technology, STELLA PHARMA CORPORATION aims to expand its business both domestically and internationally.